


Product Name : LEI-101
Cat. No. : PC-27963
CAS No. : 2250025-91-1
Molecular Formula : C₂₃H₂₆ClFN₄O₄S
Molecular Weight : 508.99
Target : Cannabinoid Receptor
Solubility : 10 mM in DMSO



Biological Activity

LEI-101 (LEI 101) is a potent, selective, orally available and peripherally restricted cannabinoid CB2 receptor agonist with binding pK_i of 7.5 (hCB2R).

LEI-101 displays 100-fold selectivity for CB2 receptors over CB1 receptors in binding assays, does not interact with other proteins of the endocannabinoid system: human FAAH (hFAAH), MAGL, NAPE-PLD and DAGL.

LEI-101 behaves as a CB2 receptor partial agonist in the β-arrestin recruitment and GTPγS assays with pEC₅₀ of 8.0 and 7.0, respectively.

LEI-101 (60 mg/kg, p.o.) does not induce cannabimimetic effects in vivo.

LEI-101 (3.0 or 10 mg/kg, p.o. and i.p.) attenuates biomarkers and histological damage of cisplatin-induced nephropathy in C57Bl6/J mice, prevents cisplatin-induced increases in serum creatinine and BUN levels.

LEI-101 attenuates cisplatin-induced renal 3-nitrotyrosine (3-NT) formation, attenuates cisplatin (Cis)-induced renal HNE adducts formation in wild type, but not in CB2R^{-/-} mice.

References

Mukhopadhyay P, et al. Br J Pharmacol. 2016 Feb;173(3):446-58.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com